Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $2.2 million.

  • Ocular Therapeutix's Change in Accured Expenses fell 4826.44% to $2.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 million, marking a year-over-year increase of 4425.51%. This contributed to the annual value of $5.2 million for FY2025, which is 4425.51% up from last year.
  • Per Ocular Therapeutix's latest filing, its Change in Accured Expenses stood at $2.2 million for Q4 2025, which was down 4826.44% from $5.4 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Change in Accured Expenses high stood at $7.9 million for Q2 2024, and its period low was -$14.0 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.0 million (2021), whereas its average is $751000.0.
  • As far as peak fluctuations go, Ocular Therapeutix's Change in Accured Expenses surged by 93031.91% in 2022, and later plummeted by 43390.41% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Change in Accured Expenses stood at $188000.0 in 2021, then surged by 930.32% to $1.9 million in 2022, then plummeted by 164.33% to -$1.2 million in 2023, then surged by 437.56% to $4.2 million in 2024, then crashed by 48.26% to $2.2 million in 2025.
  • Its Change in Accured Expenses stands at $2.2 million for Q4 2025, versus $5.4 million for Q3 2025 and $2.8 million for Q2 2025.